Preoperative fecal elastase-1 is a useful prognostic marker following curative resection of pancreatic cancer

Lim, Jin Hong; Park, Joon Seong; Yoon, Dong Sup

doi:10.1016/j.hpb.2016.12.007

Cited by 10 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this study, which included patients with stage III or IV pancreatic cancer and the reference SE level, obtained ambiguous results. Lim et al reported that a low SE level (≤200 µg/g) was a significant prognostic factor for recurrence of pancreatic cancer in patients who underwent curative resection involving any location of the pancreas [22]. As mentioned earlier, PEI depends on tumor location [10].…”

Section: Discussionmentioning

confidence: 91%

Stool Elastase as an Independent Prognostic Factor in Patients with Pancreatic Head Cancer

Hwang

Kim

Sohn

et al. 2022

JCM

View full text Add to dashboard Cite

(1) Background: Patients with pancreatic exocrine insufficiency (PEI) have an increased risk of malnutrition, which in turn increases morbidity and mortality and is frequent in pancreatic head cancer. This study aimed to analyze the utility of PEI measured using the stool elastase (SE) level to predict the prognosis of patients with pancreatic head cancer. (2) Methods: Patients who underwent pancreaticoduodenectomy for pancreatic cancer at our institution between 2011 and 2015 were included. Only patients with data on preoperative SE levels were analyzed. Patients were classified into low and high SE groups based on preoperative SE levels (low < 100 µg/g < high). (3) Results: The median preoperative SE level was 67.2 µg/g, and 84 of 143 (58.7%) patients were included in the low SE group. The two groups had significantly different overall survival (OS) and disease-free survival (DFS), and the low SE group had a worse prognosis. In multivariate analysis, SE level < 100 µg/g and lymph node metastasis were independent poor prognostic factors for OS and DFS. (4) Discussion: PEI measured using SE levels is an independent prognostic factor in patients with pancreatic head cancer undergoing pancreaticoduodenectomy. Since poor nutritional status may be related to prognosis in patients with low levels of stool elastase preoperatively, aggressive treatment may be required.

show abstract

Section: Discussionmentioning

confidence: 91%

Stool Elastase as an Independent Prognostic Factor in Patients with Pancreatic Head Cancer

Hwang

Kim

Sohn

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…That is why in recent years an attempt has been made to identify new biomarkers for early diagnosis that can also be used in screening programs in patients with various risk factors. For example, different tumor growth markers have been described for use in pancreatic juice (carcinoembryonic antigen, Duke pancreatic monoclonal antigen type 2, cathepsin E and KRAS), saliva (KRAS, methyl-CpG binding domain protein 3 like 2 and dolichyl-phosphate mannosyltransferase subunit 1, catalytic), fecal matter (KRAS mutated, CA19-9 or CA242) or in combinations between them to improve the sensitivity and specificity, but none of them have been put into clinical practice or evaluated in large population studies to assess their positive predictive value (65)(66)(67)(68). There are a number of reasons for this.…”

Section: Serological Markers and Ca19-9mentioning

confidence: 99%

Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives (Review)

et al. 2021

View full text Add to dashboard Cite

Pancreatic cancer has a dire prognosis and will represent the second leading cause of cancer death in the next 10 years. The multifactorial approach represents one of the main issues in controlling the extension of this neoplasm. In recent years, the characteristics of the tumor microenvironment, metastasis mechanisms and the relationship between immune system and neoplastic cells have been described, which has made it possible to understand the pathophysiology of pancreatic adenocarcinoma. Currently, there is a failure to provide an effective preventive method or early detection, so patients present with an advanced stage at the time of diagnosis. Despite numerous efforts, little progress has been made in clinical outcome and in improving survival in long term. Therefore, in the recent years, diverse diagnostic tests, treatments and possible approaches have been developed in the fields of radiotherapy, chemotherapy and surgery to find a combination of them that improves life expectancy in patients diagnosed with pancreatic cancer. At the moment, numerous clinical trials are being conducted to evaluate preventive diagnostic procedures such as serological markers or perfecting available imaging tests. On the other hand, implementation of immunotherapy is being studied in a neoplasm that has lagged in the application of this procedure since present possible treatments do not substantially improve quality of life. Therefore, the purpose of our study is to summarize the main progresses that have been made in the diagnosis, treatment and screening of this disease, explaining the limitations that have been observed and analyzing future prospects in the management of this illness.

show abstract

“…Эластаза является продуктом секреции ПЖ, который остается относительно стабильным при прохождении через желудочно-кишечный тракт, результаты теста не зависят от проведения ФЗТ [27,28]. Тест легко воспроизводим, для анализа требуется небольшой объем кала, подвергаемый иммуноабсорбционному анализу с моноклональными антителами.…”

Section: оценка фекальной эластазы (е-1)unclassified

“…Тем не менее была отмечена необходимость более масштабных исследований для определения диагностической значимости этого биомаркера и оптимальных условий применения в клинической практике. По данным исследования J.-H. Lim и соавт., целью которого являлась оценка влияния показателей E-1 на выживаемость больных раком поджелудочной железы (РПЖ), установлено, что снижение уровня E-1 является неблагоприятным независимым прогностическим фактором безрецидивной выживаемости для больных РПЖ после резекции [28]. D.C. Sudipta и соавт.…”

Section: оценка фекальной эластазы (е-1)unclassified

Diagnosis of the Pancreatic Functional Insufficiency

Malykh¹,

Дубцова²,

Vinokurova³

et al. 2021

EPh

View full text Add to dashboard Cite

Exo- and/or endocrine pancreatic insufficiency are the complications and diagnostic criteria of chronic pancreatitis. Recently expanded surgical activity in pancreatic diseases prolongs overall survival in such patients. However, patients’ quality of life decreases due to exo- and endocrine pancreatic insufficiency. Timely diagnosis and adequate treatment of the conditions are based on the lab assessment of pancreatic function. The paper presents diagnostic methods, their sensitivity, specificity, and diagnostic role.

show abstract

Preoperative fecal elastase-1 is a useful prognostic marker following curative resection of pancreatic cancer

Abstract: FE-1 is a simple and non-invasive predictive clinical marker for prognosis of pancreatic cancer after attempted curative resection.

Cited by 10 publications

References 48 publications

Stool Elastase as an Independent Prognostic Factor in Patients with Pancreatic Head Cancer

Stool Elastase as an Independent Prognostic Factor in Patients with Pancreatic Head Cancer

Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives (Review)

Diagnosis of the Pancreatic Functional Insufficiency

Contact Info

Product

Resources

About